Literature DB >> 12633144

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

Chris Zarow1, Scott A Lyness, James A Mortimer, Helena C Chui.   

Abstract

CONTEXT: Alzheimer disease (AD) and Parkinson disease (PD) are associated with neuronal degeneration in major subcortical nuclei, but few studies have examined the neuronal degeneration in these nuclei concurrently.
OBJECTIVE: To identify clinical and pathological correlates of neuronal loss in the nucleus basalis (NB), locus coeruleus (LC), and substantia nigra pars compacta (SN) in AD and PD.
DESIGN: The study sample comprised 86 cases with pathologically confirmed AD, 19 cases with PD, and 13 healthy elderly control subjects. The number of nucleolated neurons was counted in representative sections of the NB, LC, and SN. Effect sizes (ES) were computed to determine the standardized difference in cell counts relative to healthy controls.
RESULTS: Cases of AD showed the greatest neuronal loss in the LC (ES = 3.16) followed by the NB (ES = 1.10), but variable loss in the SN (ES = 0.16). Cases of PD also showed the greatest neuronal loss in the LC (ES = 6.47), followed by the SN (ES = 2.58) and the NB (ES = 0.85). Significant correlations were found between the number of neurons in the NB and LC in PD (r = 0.54, P<.05), as well as AD (r = 0.24, P<.05). The duration of illness correlated with greater neuronal loss in the LC and NB in AD, and greater neuronal loss in the SN in PD.
CONCLUSIONS: For both AD and PD the greatest neuronal loss was found in the LC. In AD, neuronal loss was most severe and best correlated with the duration of illness in the LC, rather than in NB as traditionally expected. Correlations between neuronal loss in the LC and NB (but not SN) in both PD and AD suggest that the former 2 nuclei may share common pathogenetic susceptibilities. Given the prominent loss of neurons in the LC, detection and treatment of noradrenergic deficiencies warrant attention in both AD and PD.

Entities:  

Mesh:

Year:  2003        PMID: 12633144     DOI: 10.1001/archneur.60.3.337

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  309 in total

1.  The human locus coeruleus 3-D stereotactic anatomy.

Authors:  P Fernandes; J Regala; F Correia; A J Gonçalves-Ferreira
Journal:  Surg Radiol Anat       Date:  2012-05-26       Impact factor: 1.246

2.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 3.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

4.  Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease.

Authors:  Aron S Buchman; Sukriti Nag; Joshua M Shulman; Andrew S P Lim; Veronique G J M VanderHorst; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

5.  Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Authors:  Christian Pifl; Stephen J Kish; Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 8.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 9.  Pathophysiology of somatosensory abnormalities in Parkinson disease.

Authors:  Antonella Conte; Nashaba Khan; Giovanni Defazio; John C Rothwell; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

10.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.